Moody Aldrich Partners LLC Purchases New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Moody Aldrich Partners LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,683 shares of the company’s stock, valued at approximately $205,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Chartwell Investment Partners LLC grew its position in shares of Neurocrine Biosciences by 208.9% in the second quarter. Chartwell Investment Partners LLC now owns 18,900 shares of the company’s stock valued at $2,306,000 after purchasing an additional 12,782 shares during the period. Shine Investment Advisory Services Inc. grew its position in shares of Neurocrine Biosciences by 76.4% in the second quarter. Shine Investment Advisory Services Inc. now owns 247 shares of the company’s stock valued at $30,000 after purchasing an additional 107 shares during the period. Raymond James & Associates grew its position in shares of Neurocrine Biosciences by 11.1% in the second quarter. Raymond James & Associates now owns 108,321 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,860 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Neurocrine Biosciences by 17.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,207 shares of the company’s stock valued at $2,709,000 after purchasing an additional 3,238 shares during the period. Finally, Vident Investment Advisory LLC grew its position in shares of Neurocrine Biosciences by 58.9% in the second quarter. Vident Investment Advisory LLC now owns 10,264 shares of the company’s stock valued at $1,252,000 after purchasing an additional 3,805 shares during the period. Institutional investors own 96.93% of the company’s stock.

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 5,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $120.00, for a total transaction of $600,000.00. Following the completion of the sale, the insider now directly owns 31,021 shares in the company, valued at $3,722,520. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Haig P. Bozigian sold 61,555 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $114.94, for a total transaction of $7,075,131.70. Following the sale, the insider now owns 157,727 shares of the company’s stock, valued at $18,129,141.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 96,894 shares of company stock valued at $11,119,097. Company insiders own 4.30% of the company’s stock.

NBIX has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Neurocrine Biosciences from $122.00 to $134.00 and gave the company an “overweight” rating in a research report on Thursday, June 18th. BidaskClub lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating and set a $145.00 price target on the stock in a research note on Wednesday, July 15th. TheStreet raised shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research note on Wednesday, May 13th. Finally, Wedbush started coverage on shares of Neurocrine Biosciences in a research note on Monday, June 8th. They issued an “outperform” rating and a $147.00 price target on the stock. Six research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $135.47.

NBIX stock traded down $1.36 during trading on Friday, reaching $120.36. 640,983 shares of the stock were exchanged, compared to its average volume of 667,582. The company has a current ratio of 6.90, a quick ratio of 6.75 and a debt-to-equity ratio of 0.71. The business has a 50 day moving average price of $126.27 and a 200-day moving average price of $107.84. Neurocrine Biosciences, Inc. has a 1 year low of $72.14 and a 1 year high of $136.26. The firm has a market capitalization of $11.18 billion, a price-to-earnings ratio of 51.66 and a beta of 1.34.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Neurocrine Biosciences had a net margin of 19.90% and a return on equity of 37.53%. The company had revenue of $237.10 million for the quarter, compared to the consensus estimate of $226.29 million. During the same period in the previous year, the firm earned $0.29 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 71.3% compared to the same quarter last year. On average, research analysts anticipate that Neurocrine Biosciences, Inc. will post 3.06 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Story: Intrinsic Value and Stock Selection

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.